X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aventis Pharma with Abbott India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs ABBOTT INDIA - Comparison Results

SANOFI INDIA    Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

ABBOTT INDIA 
   Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SANOFI INDIA ABBOTT INDIA SANOFI INDIA/
ABBOTT INDIA
 
P/E (TTM) x 34.3 39.4 87.2% View Chart
P/BV x 6.9 11.4 60.5% View Chart
Dividend Yield % 1.3 0.5 243.4%  

Financials

 SANOFI INDIA   ABBOTT INDIA
EQUITY SHARE DATA
    SANOFI INDIA
Dec-16
ABBOTT INDIA
Mar-17
SANOFI INDIA/
ABBOTT INDIA
5-Yr Chart
Click to enlarge
High Rs4,5605,190 87.9%   
Low Rs4,4004,351 101.1%   
Sales per share (Unadj.) Rs1,028.51,382.9 74.4%  
Earnings per share (Unadj.) Rs129.0130.2 99.1%  
Cash flow per share (Unadj.) Rs186.0137.9 134.8%  
Dividends per share (Unadj.) Rs68.0040.00 170.0%  
Dividend yield (eoy) %1.50.8 181.0%  
Book value per share (Unadj.) Rs753.6652.7 115.5%  
Shares outstanding (eoy) m23.0321.25 108.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.43.4 126.3%   
Avg P/E ratio x34.736.6 94.8%  
P/CF ratio (eoy) x24.134.6 69.6%  
Price / Book Value ratio x5.97.3 81.3%  
Dividend payout %52.730.7 171.6%   
Avg Mkt Cap Rs m103,174101,373 101.8%   
No. of employees `0003.63.1 117.5%   
Total wages/salary Rs m3,5923,453 104.0%   
Avg. sales/employee Rs Th6,537.79,531.9 68.6%   
Avg. wages/employee Rs Th991.41,119.9 88.5%   
Avg. net profit/employee Rs Th819.8897.3 91.4%   
INCOME DATA
Net Sales Rs m23,68629,387 80.6%  
Other income Rs m708576 122.8%   
Total revenues Rs m24,39429,963 81.4%   
Gross profit Rs m5,2813,973 132.9%  
Depreciation Rs m1,313164 799.1%   
Interest Rs m1520 73.5%   
Profit before tax Rs m4,6614,365 106.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,6911,598 105.8%   
Profit after tax Rs m2,9702,767 107.4%  
Gross profit margin %22.313.5 164.9%  
Effective tax rate %36.336.6 99.1%   
Net profit margin %12.59.4 133.2%  
BALANCE SHEET DATA
Current assets Rs m15,67318,906 82.9%   
Current liabilities Rs m6,6786,297 106.1%   
Net working cap to sales %38.042.9 88.5%  
Current ratio x2.33.0 78.2%  
Inventory Days Days7662 122.2%  
Debtors Days Days2222 103.1%  
Net fixed assets Rs m8,0981,159 698.8%   
Share capital Rs m230213 108.4%   
"Free" reserves Rs m17,08813,657 125.1%   
Net worth Rs m17,35613,869 125.1%   
Long term debt Rs m00-   
Total assets Rs m25,40020,638 123.1%  
Interest coverage x311.7215.0 145.0%   
Debt to equity ratio x00-  
Sales to assets ratio x0.91.4 65.5%   
Return on assets %11.813.5 87.0%  
Return on equity %17.119.9 85.8%  
Return on capital %26.931.6 85.2%  
Exports to sales %24.50-   
Imports to sales %28.00-   
Exports (fob) Rs m5,801NA-   
Imports (cif) Rs m6,627NA-   
Fx inflow Rs m7,1450-   
Fx outflow Rs m6,8460-   
Net fx Rs m2990-   
CASH FLOW
From Operations Rs m3,2263,072 105.0%  
From Investments Rs m-1,555-1,554 100.1%  
From Financial Activity Rs m-1,818-898 202.5%  
Net Cashflow Rs m-147621 -23.7%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 60.4 75.0 80.5%  
Indian inst/Mut Fund % 14.4 7.9 182.3%  
FIIs % 14.6 0.1 14,600.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 17.1 61.4%  
Shareholders   15,184 18,270 83.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SANOFI INDIA With:   TORRENT PHARMA  NATCO PHARMA  BIOCON LTD  IPCA LABS  ALKEM LABORATORIES  

Compare SANOFI INDIA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Day up 260 Points; Pharma Stocks Top Gainers(Closing)

After opening the day in red, share markets in India witnessed positive trading activity throughout the day and ended the day on a positive note.

Related Views on News

ABBOTT INDIA at All Time High; BSE HEALTHCARE Index Down 0.7%

Jun 22, 2018 | Updated on Jun 22, 2018

ABBOTT INDIA share price has hit an all time high at Rs 7,420 (up 1.67%). The BSE HEALTHCARE Index is down by 0.74%. Among the top gainers in the BSE HEALTHCARE Index today are ABBOTT INDIA (up 1.67%) and GSK PHARMA (up 0.01%). The top losers include PFIZER (down 0.00%) and IPCA LABS (down 0.01%).

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

Will You Dump Your Client if You're Busy? Inox Wind's Auditor Just Did...(The 5 Minute Wrapup)

Jun 14, 2018

After Inox Wind, you may see more auditors resigning And the reasons can be as funny as they can get.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Should You Invest In Mirae Asset Healthcare Fund?(Outside View)

Jun 15, 2018

Mirae Asset Mutual Fund launches NFO - Mirae Asset Helathcare Fund.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Jun 22, 2018 (Close)

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA 5-YR ANALYSIS

COMPARE SANOFI INDIA WITH

MARKET STATS